Sutro Biopharma shares surge 19.21% intraday after first cohort dosed in Phase 1 trial of STRO-004, a next-generation tissue factor ADC.

Sutro Biopharma surged 19.21% intraday following the announcement that the first cohort of patients has been dosed in its Phase 1 trial of STRO-004, a next-generation Tissue Factor-targeting antibody-drug conjugate (ADC) for solid tumors. The trial, evaluating the ADC’s safety and preliminary anti-tumor activity in advanced cancers, marks a critical milestone for the clinical-stage biotech. STRO-004, engineered using Sutro’s proprietary cell-free platform, aims to deliver best-in-class stability and potency, with initial clinical data expected in mid-2026. The news underscores progress in Sutro’s pipeline, which focuses on addressing unmet needs in oncology through novel ADCs. While a concurrent 1-for-10 reverse stock split was announced to meet Nasdaq requirements, the trial milestone was the primary catalyst for the intraday rally, reflecting investor optimism about the program’s potential to advance treatment options for TF-expressing cancers.